Mode
Text Size
Log in / Sign up
N/A Completed N=25

Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg

Source: ClinicalTrials.gov NCT00195338 ↗
Enrolled (actual)
25
Serious AEs
24.0%
Results posted
Jan 2012
Primary outcomePrimary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 56; 24 percentage of participants

Summary

The purpose of the study is to determine the long term safety of Enbrel in adults with active rheumatoid arthritis in Luxemburg. This is a post-marketing surveillance study in rheumatology practice patients. All patients initiated with Enbrel will be observed from the start of the study in Feb 2003 for a period of at least 5 years.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
56; 24 —
SECONDARY
Percentage of Participants With Completion of Study Treatment
100; 100; 92; 80; 80; 80 —
SECONDARY
Change From Baseline in Number of Joints With Active Synovitis at Months 6, 12, 18, 30, 42, 54 and 66
26.5; -20.2; -20.3; -21.4; -19.5; -24.4 —
SECONDARY
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Months 6, 12, 18, 30, 42, 54 and 66
32.4; -13.7; -17.0; -17.8; -10.4; -20.0 —
SECONDARY
Mean Dose of Concomitant Methotrexate (MTX) and Steroids
— —

Eligibility Criteria

Inclusion Criteria

  • Have moderate to severe active rheumatoid arthritis
  • Be aged of 17 years or more
  • Have inadequate response to DMards
  • Give written informed consent
  • Physician decides to prescribe Enbrel

Exclusion Criteria

n/a

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00195338). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search